Abstract Somatic gene mutations can alter the vulnerability of cancer cells to T-cell-based immunotherapies. Here we perturbed genes in human melanoma cells to mimic loss-of-function mutations involved in resistance to these therapies, by using a genome-scale CRISPR–Cas9 library that consisted of around 123,000 single-guide RNAs, and profiled genes whose loss in tumour cells impaired the...
Tag: <span>Cancer Immunotherapy</span>
Post
New study identifies essential genes for cancer immunotherapy
A new study identifies genes that are necessary in cancer cells for immunotherapy to work, addressing the problem of why some tumors don’t respond to immunotherapy or respond initially but then stop as tumor cells develop resistance to immunotherapy. The study, from the National Cancer Institute (NCI), was led by Nicholas Restifo, M.D., a senior...
Post
A new T-cell population for cancer immunotherapy
Scientists at the University of Basel in Switzerland have, for the first time, described a new T cell population that can recognize and kill tumor cells. The open access journal eLife has published the results. T lymphocytes (short T cells) are a special type of cells that recognize germs and protect our body from infections. Their second important...
Post
Cancer immunotherapy may work in unexpected way
Researchers have found that a cancer therapy may prompt a type of immune cell called a macrophage (illustrated above) to attack cancer. Antibodies to the proteins PD-1 and PD-L1 have been shown to fight cancer by unleashing the body’s T cells, a type of immune cell. Now, researchers at the Stanford University School of...
Post
Antibody for fighting cancer emerges
Killer T cells surround a cancer cell. While studying the underpinnings of multiple sclerosis, investigators at Brigham and Women’s Hospital came across important clues for how to treat a very different disease: cancer. In a paper published in Science Immunology, a group of researchers led by neurologist Howard Weiner, MD, describe an antibody that can...